Stock events for Option Care Health, Inc. (OPCH)
Option Care Health's stock price has declined over the past six months. Insider selling, particularly by Director Pate R. Carter, contributed to a net selling trend. While Q4 2025 results met expectations, full-year 2026 revenue guidance slightly missed analyst estimates. The stock declined sharply in March 2026 due to a "risk-off macro environment", but surged following a US-Iran ceasefire.
Demand Seasonality affecting Option Care Health, Inc.’s stock price
The demand for Option Care Health's products and services is influenced by the nature of acute and chronic therapies. The broader home infusion therapy market is experiencing significant growth, projected to reach $35.69 billion by 2025, driven by a shift towards healthcare delivery at home and the development of specialty medicines.
Overview of Option Care Health, Inc.’s business
Option Care Health, Inc. is a healthcare provider specializing in home and alternate site infusion services across the United States. The company operates within the Healthcare sector, primarily in the Medical Care Facilities and Hospitals/Inpatient Services industry. Option Care Health offers a comprehensive range of injectable therapies and services, including anti-infective therapy, nutrition and hydration support, immunoglobulin infusion therapies, pain management, and specialty pharmaceuticals. They also provide treatments for various complex and chronic conditions.
OPCH’s Geographic footprint
Option Care Health serves patients in all 50 states and Puerto Rico. The company operates through a national network of infusion pharmacies and nursing professionals, supported by over 8,000 team members, including more than 5,000 clinicians, allowing them to deliver customized care plans and in-home nursing visits.
OPCH Corporate Image Assessment
Option Care Health maintains a strong brand reputation, evidenced by consistently high patient satisfaction scores and a Net Promoter Score of 70+.
Ownership
Option Care Health's ownership is predominantly institutional, with approximately 98.05% of the company's stock held by institutional investors. Key institutional holders include BlackRock, Inc., The Vanguard Group, Inc., and Wellington Management Group LLP. Insider holdings represent around 1.27% of the total shares.
Ask Our Expert AI Analyst
Price Chart
$28.14